Abstract: A remote control for controlling a medical apparatus having at least one driven movable components is provided. The remote control comprises a sensor configured to detect a position and a motion of the remote control, and at least one release switch. The remote control is configured to emit a control signal capable of controlling a motion of the at least one driven movable component according to a motion of the remote control detected by the sensor when a control of the motion of the at least one driven movable component is released by actuating the at least one release switch.

Abstract: A remote control for controlling a medical apparatus having at least one driven movable components is provided. The remote control comprises a sensor configured to detect a position and a motion of the remote control, and at least one release switch. The remote control is configured to emit a control signal capable of controlling a motion of the at least one driven movable component according to a motion of the remote control detected by the sensor when a control of the motion of the at least one driven movable component is released by actuating the at least one release switch.

Abstract: A remote control for controlling a medical apparatus having at least one driven movable components is provided. The remote control comprises a sensor configured to detect a position and a motion of the remote control, and at least one release switch. The remote control is configured to emit a control signal capable of controlling a motion of the at least one driven movable component according to a motion of the remote control detected by the sensor when a control of the motion of the at least one driven movable component is released by actuating the at least one release switch.

Abstract: A remote control for controlling a medical apparatus having at least one driven movable components is provided. The remote control comprises a sensor configured to detect a position and a motion of the remote control, and at least one release switch. The remote control is configured to emit a control signal capable of controlling a motion of the at least one driven movable component according to a motion of the remote control detected by the sensor when a control of the motion of the at least one driven movable component is released by actuating the at least one release switch.

Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.

Abstract: A method of treating a human patient with depressive and/or anxiety symptoms which includes administering an effective amount of a V1B receptor antagonist and/or CRHR1 antagonist to the patient in need thereof, wherein the patient's genome has certain polymorphoric variants.

Abstract: The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.

Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.

Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The invention relates inter alia to methods for predicting the response of patients with depressive symptoms and/or anxiety symptoms to treatment with a CRHR1 antagonist, and algorithms, kits, microarrays, probes and or/primers for use in such methods.

Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis patient to become less susceptible or resistant to treatment with interferon ?, said method comprising determining in a sample obtained from said patient the presence of one or more SNP(s) selected from the group consisting of SNPs defined by the sequences of SEQ ID NOs 12, 17, 2, 3, 5, 7, 8, 1, 4, 6, 9, 10, 11, 13, 14, 15 and 16, wherein the presence of one or more of said SNP(s) in said sample is indicative for said predisposition.

Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-? (IFN-?) and/or interferon-? (IFN-?) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means.

Abstract: The present invention relates to an oligo- or polynucleotide which can be used in the diagnosis and therapy of restless legs syndrome (RLS). Furthermore, the invention relates to methods of diagnosing a predisposition for or RLS and a method for selecting a therapy to prevent and treat RLS. Moreover, a method for determining the dose of a drug used for treating a patient suffering from RLS and a method to test the efficacy of a drug used for treating RLS in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias as well as the use of a drug effective in treating RLS for testing the efficacy of said drug in treating other dopaminergic diseases, sleep disorders or spinocerebellar ataxias.

Abstract: The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.

Abstract: The present invention relates to a method of diagnosing a predisposition of a multiple sclerosis (MS) patient for responsiveness to a treatment of MS by administration of interferon-? (IFN-?) and/or interferon-? (IFN-?) and means to perform the method. Furthermore, the invention relates to a method of diagnosing a predisposition of a patient for developing multiple sclerosis (MS) and corresponding means.

Abstract: The present invention relates to a method of classifying an individual comprising analyzing the nucleic acid of a sample taken from said patient for nucleotide polymorphisms in a haplotype block comprising the gene encoding FKBP51 and/or determining the expression level of FKBP51 in said sample. In a preferred embodiment, the invention provides a method of predicting the response to antidepressant therapy. Furthermore, a method of developing an anti-depressant drug, and pharmaceutical compositions are provided.